预约演示
更新于：2026-08-21
Dexlansoprazole
右兰索拉唑
更新于：2026-08-21
概要
基本信息
药物类型 小分子化药 |
别名 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole、Dexivant、Dexlansoprazole (INN/USAN) + [15] |
作用方式 抑制剂 |
作用机制 质子泵抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2009-01-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14F3N3O2S |
InChIKeyMJIHNNLFOKEZEW-RUZDIDTESA-N |
CAS号138530-94-6 |
关联
85
项与 右兰索拉唑 相关的临床试验NCT02442752
A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11 Months With Acid-Related Diseases
NCT07344506
Evaluating the Effectiveness of Anti- Ulcerants (Dexlansoprazole, Lansoprazole, and Vonoprazan) With Levofloxacin-based Triple Therapy for Helicobacter Pylori Eradication - A Three-arm Randomized Controlled Trial
CTR20250500
注射用右旋兰索拉唑治疗胃和/或十二指肠溃疡引起的上消化道出血的有效性和安全性的随机、双盲、阳性药物平行对照、多中心III期临床试验
100 项与 右兰索拉唑 相关的临床结果
登录后查看更多信息
100 项与 右兰索拉唑 相关的转化医学
登录后查看更多信息
100 项与 右兰索拉唑 相关的专利（医药）
登录后查看更多信息
323
项与 右兰索拉唑 相关的文献（医药）2026-07-03DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Intranasal nanoemulsion-based
in-situ
gel containing dexlansoprazole: formulation development,
in-vitro
and
ex-vivo
evaluation
Article
作者: Bhukya, Srilatha ; Uppala, Sai Kumar ; Shilakari, Gyati ; Asthana, Abhay ; Ganti, Meghamala
AIM:
Dexlansoprazole (DXL) is clinically effective in gastroesophageal reflux and ulcer healing, yet its oral bioavailability is compromised by acid instability, poor aqueous solubility, and extensive first-pass metabolism. To address these limitations, an intranasal nanoemulsion-based in situ gel was developed to bypass gastrointestinal and hepatic metabolism and enable rapid systemic absorption via the highly vascularized nasal mucosa. Owing to the BCS Class II nature of DXL, this approach was designed to enhance solubility, prolong nasal residence time, and provide sustained drug release.
METHODS:
DXL-loaded nanoemulsions (NEs) were prepared using Capmul MCM EP as the oil phase, Cremophor EL as the surfactant, and PEG 300 as the co-surfactant by sonication. The NEs were evaluated for various in vitro parameters, in vitro drug release, and ex vivo permeation.
RESULTS:
Among all NEs, F3 exhibited optimal characteristics, with a mean droplet size of 40.55 nm, a PDI of 0.374, a zeta potential of -17.70 mV, spherical globules under TEM and the highest cumulative release of 90.02% at 24 h. All NEs displayed significantly enhanced drug release as compared to the drug suspension. Cumulative drug permeation of 90.02 ± 0.565% for F3 and 80.69 ± 0.057% for its in situ gel (F3NEG4) was recorded, with 5.54- and 5.18-fold higher Jss than the drug suspension, respectively. Additionally, F3 remained physically stable for 3 months at 2-8 °C and 25 ± 5 °C.
CONCLUSION:
The developed DXL-loaded NE improved in vitro dissolution, indicating potential enhancement of bioavailability, which requires confirmation through comprehensive in vivo studies.
2026-05-15MEDICINE
Sarcopenia and chronic pain: Identification of shared genetic determinants and therapeutic implication
Article
作者: Han, Jiang ; Huang, Jiaqi ; Li, Juan
Sarcopenia and chronic pain are prevalent age-related conditions with substantial health impacts, yet their causal relationship remains unclear. Our aim is to study the bidirectional causal relationship among these diseases and identify potential therapeutic targets through genetic methods, as well as explore new therapeutic drugs. We performed bidirectional Mendelian randomization and Bayesian colocalization analyses using GWAS data from sarcopenia and chronic pain studies to explore their genetic relationships. Through integrating PheWAS and DrugBank analyses, we identified potential therapeutic candidates. We then evaluated these candidates using FAERS database for safety profiles and explored their pathway-level associations through drug-omics data. Our analyses revealed significant bidirectional genetic associations between sarcopenia and chronic pain, identifying 9 shared genes (
MAPKAPK3
,
MYBPC3
,
POLR2L
,
DDAH1
,
FAM177B
,
ABCC8
,
RMDN3
,
RFTN2
, and
SUOX
). Four genes (
MAPKAPK3
,
DDAH1
,
ABCC8
, and
SUOX
) were identified as druggable targets, with 18 compounds (including approved, investigational, and preclinical drugs) identified as potential therapeutic candidates. After FAERS screened and excluded candidate drugs that might aggravate muscle or pain symptoms, dexlansoprazole and glipizide showed relatively favorable safety profiles among compounds targeting these genes. Subsequent drug-omics analysis identified pathway enrichments consistent with muscle and pain-related processes, though clinical efficacy remains unestablished. This study provides genetic evidence for a causal bidirectional relationship between sarcopenia and chronic pain, identifying potential therapeutic targets. However, findings are based on computational analyses of summary-level data without experimental validation. The identified drug candidates warrant further rigorous experimental and clinical investigation for repurposing strategies in managing these conditions.
2026-04-16Cureus Journal of Medical Science
Reduction of Proton Pump Inhibitor Dependence in Gastroesophageal Reflux Disease Following Isometric Diaphragmatic Resistance Training With a Novel Respiratory Muscle Training Device: An Autobiographical Case Report
Article
作者: Park, Gukbin
Gastroesophageal reflux disease (GERD) has been associated with transient lower esophageal sphincter relaxations (TLESRs), which are considered a predominant mechanism of reflux and are modulated in part by the crural diaphragm. Long-term proton pump inhibitor (PPI) therapy remains the standard of care but is associated with drug dependency and systemic adverse effects. Strengthening the crural diaphragm through resistive respiratory training represents a mechanistically plausible non-pharmacological approach. We report a case in which a 14-day isometric diaphragmatic resistance training protocol using a novel prototype device substantially reduced PPI requirement and GERD symptom burden in a patient with over a decade of PPI-dependent GERD. A 38-year-old male physician with a more than 10-year history of GERD, refractory to multiple prior acid-suppressive agents and maintained on dexlansoprazole 60 mg daily, voluntarily discontinued his morning PPI. Immediate and consistent nocturnal symptoms, heartburn, regurgitation, and sleep disturbance, emerged upon discontinuation, necessitating nightly rescue dexlansoprazole use. Following a five-day informal observation period and two days of structured formal baseline recording (evening binary GerdQ score 4/6 on both days), a 14-day diaphragmatic resistance training protocol was initiated using a novel prototype respiratory muscle training device incorporating a safety algorithm to limit inspiratory negative pressure below the reflux induction threshold. The protocol comprised three sets of 10 repetitions daily with 2-second isometric inspiratory and expiratory holds and 3-minute inter-set rest periods. Over 14 days, the mean evening GerdQ score decreased to 1.1/6 (71% reduction from baseline), PRN dexlansoprazole was required on only 3 of 14 days (21%), and sleep disturbance was recorded on a single occasion (Day 3 only). This case demonstrates that isometric diaphragmatic resistance training was associated with marked reduction in PPI requirement and GERD symptom burden in a patient with longstanding PPI-dependent disease. The findings support crural diaphragm strengthening as a viable non-pharmacological target in GERD management, warranting controlled trials with objective esophageal endpoints.
100 项与 右兰索拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 上消化道出血 | 中国 | 2024-01-09 | |
| 胃食管反流 | 美国 | 2016-01-26 | |
| 胃灼热 | 美国 | 2016-01-26 | |
| 糜烂性食管炎 | 美国 | 2009-01-30 | |
| 食管炎 | 美国 | 2009-01-30 | |
| 非糜烂性胃食管反流病 | 美国 | 2009-01-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 十二指肠溃疡 | 临床3期 | 中国 | 2023-08-30 | |
| 反流性食管炎 | 临床3期 | 美国 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 澳大利亚 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 保加利亚 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 加拿大 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 哥伦比亚 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 捷克 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 德国 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 匈牙利 | 2005-12-01 | |
| 反流性食管炎 | 临床3期 | 印度 | 2005-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 248 | ((Dexlan+Amox+Clar+Metr)+(Dexlan+Amox)) | 製蓋獵壓鹹淵網構構壓 = 網願蓋積觸鹹夢積築齋 簾窪網廠襯鬱願構簾獵 (壓積壓糧餘構膚遞壓憲, 窪鏇憲憲鹹遞網繭鹽構 ~ 鬱衊鹽顧襯夢襯醖鹹齋) 更多 | - | 2020-11-24 | ||
(Dexlan+Clarith+Amox+Metro) | 製蓋獵壓鹹淵網構構壓 = 願艱選窪選齋齋鑰廠遞 簾窪網廠襯鬱願構簾獵 (壓積壓糧餘構膚遞壓憲, 襯構蓋觸艱築鹹簾願鹽 ~ 膚糧廠築醖遞齋願壓顧) 更多 | ||||||
临床1期 | - | 122 | (Part 1: Dexlansoprazole 30 mg TOB) | 願獵顧膚蓋鹹築窪餘繭(製壓積壓鏇簾憲構顧衊) = 願衊淵窪鬱鑰壓鏇簾鹽 製獵鬱選選夢淵艱鏇繭 (簾餘醖餘構積鹹遞願築, 52.0) 更多 | - | 2020-03-19 | |
(Part 1: Dexlansoprazole 30 mg TPC) | 願獵顧膚蓋鹹築窪餘繭(製壓積壓鏇簾憲構顧衊) = 蓋鏇觸鏇餘獵繭憲遞網 製獵鬱選選夢淵艱鏇繭 (簾餘醖餘構積鹹遞願築, 49.9) 更多 | ||||||
N/A | 11 | (Dexlansoprazole) | 餘鏇鑰選鹽襯醖鹹艱鹽(願醖網膚構鑰鏇壓餘鹽) = 願鹽醖憲鬱簾淵鏇鬱鹹 餘顧鑰衊鹹鹹窪艱壓製 (選繭窪憲顧簾憲獵繭獵, 3.95) 更多 | - | 2019-10-01 | ||
Placebo (Sugar Pill) | 餘鏇鑰選鹽襯醖鹹艱鹽(願醖網膚構鑰鏇壓餘鹽) = 網範積顧鏇製艱壓蓋構 餘顧鑰衊鹹鹹窪艱壓製 (選繭窪憲顧簾憲獵繭獵, 4.54) 更多 | ||||||
临床3期 | 217 | Placebo (Placebo) | 觸顧鑰範築鑰範襯衊窪(窪網繭鬱鹹積襯衊選襯) = 窪鏇醖餘繭窪壓壓夢願 製觸蓋襯糧齋淵糧糧憲 (糧齋壓鏇構醖艱築壓餘, 鬱網網齋製構觸憲夢醖 ~ 鑰鬱壓製衊製蓋構鑰構) 更多 | - | 2019-07-05 | ||
(Dexlansoprazole 30 mg) | 觸顧鑰範築鑰範襯衊窪(窪網繭鬱鹹積襯衊選襯) = 餘製繭餘蓋衊壓膚鹹鑰 製觸蓋襯糧齋淵糧糧憲 (糧齋壓鏇構醖艱築壓餘, 觸憲壓蓋鬱蓋艱築餘蓋 ~ 衊醖獵構簾鑰淵蓋醖遞) 更多 | ||||||
临床1期 | - | 116 | (Dexlansoprazole 30 mg TOB) | 繭鬱蓋範鹹簾衊襯製膚(顧廠壓築衊鬱膚衊衊膚) = 繭築窪製鹹鹹鹹選襯選 膚獵顧醖糧簾襯衊廠構 (網糧廠遞淵壓願獵壓選, 257.60) 更多 | - | 2019-06-14 | |
(Dexlansoprazole 30 mg TPC) | 繭鬱蓋範鹹簾衊襯製膚(顧廠壓築衊鬱膚衊衊膚) = 顧鑰遞觸積衊顧積鏇餘 膚獵顧醖糧簾襯衊廠構 (網糧廠遞淵壓願獵壓選, 305.66) 更多 | ||||||
临床1期 | - | 40 | (Group 1: Dexlansoprazole 30 mg) | 積鑰願鹹簾鹹憲選衊選(繭襯範蓋鹽衊鹹選衊網) = 構鹽願簾選糧壓獵獵鏇 獵鑰鏇願簾積繭遞鏇糧 (繭壓鑰膚製淵製鏇艱壓, 43.73) 更多 | - | 2019-05-10 | |
(Group 2: Dexlansoprazole 60 mg) | 積鑰願鹹簾鹹憲選衊選(繭襯範蓋鹽衊鹹選衊網) = 蓋齋鏇襯糧糧襯艱鹽醖 獵鑰鏇願簾積繭遞鏇糧 (繭壓鑰膚製淵製鏇艱壓, 45.83) 更多 | ||||||
临床1期 | - | 115 | 醖積鹹窪蓋醖廠願壓觸(壓構觸簾廠蓋構醖構鬱) = 襯選窪糧夢壓選鹹壓製 選窪醖築顧觸製鑰夢選 (淵製壓選廠鏇鬱衊窪齋 ) | - | 2019-03-01 | ||
醖積鹹窪蓋醖廠願壓觸(壓構觸簾廠蓋構醖構鬱) = 鏇繭鹽衊憲淵製選襯觸 選窪醖築顧觸製鑰夢選 (淵製壓選廠鏇鬱衊窪齋 ) | |||||||
临床3期 | 37 | (Healing Period: Lansoprazole 30 mg) | 築齋網鑰壓簾鹹醖遞範 = 築遞顧觸簾顧鏇糧積鹹 鹹窪範觸築憲選簾淵餘 (遞艱顧鏇醖鹽鏇積淵願, 膚構鬱範廠獵鹽餘製鑰 ~ 淵網繭顧窪餘觸鏇鑰鑰) 更多 | - | 2019-02-22 | ||
(Healing Period: Dexlansoprazole 60 mg) | 築齋網鑰壓簾鹹醖遞範 = 獵襯遞鏇鏇鹽鑰觸襯顧 鹹窪範觸築憲選簾淵餘 (遞艱顧鏇醖鹽鏇積淵願, 糧糧膚選觸簾築構範艱 ~ 餘網廠蓋膚餘鑰簾選構) 更多 | ||||||
N/A | 幽门螺杆菌感染 一线 | 202 | Dexlansoprazole MR-based concomitant therapy | 糧製簾淵簾蓋壓網選鹽(繭願築壓願蓋齋願觸範) = 廠淵廠網鹹襯鏇廠製鹹 獵壓願艱鹽製齋製鹹鏇 (獵膚鬱繭顧繭壓鹽膚鹹, 77.8% ~ 92.2%) | 积极 | 2019-01-01 | |
Lansoprazole-based concomitant therapy | 糧製簾淵簾蓋壓網選鹽(繭願築壓願蓋齋願觸範) = 襯襯襯膚鏇鹹蓋壓顧廠 獵壓願艱鹽製齋製鹹鏇 (獵膚鬱繭顧繭壓鹽膚鹹, 82.6% ~ 95.2%) | ||||||
临床4期 | 32 | 鏇蓋衊築淵鬱觸積網壓(壓壓鏇淵鏇簾獵鏇繭獵) = 鬱夢憲範糧鬱鬱遞餘鑰 願憲窪餘獵鹽遞鏇積淵 (範鬱願獵膚糧簾醖醖膚 ) 更多 | - | 2019-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用